A PYMNTS Company

EU: In landmark sanction, EU fines $195M for pay-for-delay agreements

By  |  June 19, 2013

The same week the US Supreme Court ruled that drugmakers can be sued for so-called pay-for-delay agreements, the European Commission has fined nine pharmaceutical drug companies – an unprecedented sanction – for paying to keep generic drugs off the shelves. The fines, which amount to more than $195 million, follow a report by the Commission completed in 2009 which resolved that consumers paid up to 20 percent more for prescription drugs because of these agreements. Those that were fined include Denmark-based Lundbeck and India-based Ranbaxy. In a statement, European Commissioner Joaquin Almuna told reporters that the watchdog “will not tolerate such anticompetitive practices.”

Full Content: Yahoo News

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.